Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Nirali N ShahDeepa BhojwaniKeith J AugustAndré BaruchelYves BertrandJessica BoklanLuciano Dalla-PozzaRobyn DennisNobuko HijiyaFranco LocatelliPaul L MartinFrançoise MechinaudJohn MoppettSusan R RheingoldClaudine SchmittTanya M TrippettMeina LiangKemal BalicXia LiInna VainshteinNai Shun YaoIra PastanAlan S WaynePublished in: Pediatric blood & cancer (2020)
Despite a signal for clinical activity, this phase 2 study was terminated at interim analysis for a CR rate that did not reach the stage 1 target. Preclinical data suggest enhanced efficacy of moxetumomab pasudotox via continuous infusion or in combination regimens; thus, further studies designed to optimize the efficacy and safety of moxetumomab pasudotox in pediatric ALL may be warranted.
Keyphrases
- acute lymphoblastic leukemia
- open label
- allogeneic hematopoietic stem cell transplantation
- acute myeloid leukemia
- double blind
- low dose
- electronic health record
- placebo controlled
- diffuse large b cell lymphoma
- single cell
- multiple myeloma
- clinical trial
- early life
- study protocol
- machine learning
- mesenchymal stem cells
- cell fate
- bone marrow